Stifel analyst Stephen Willey raised the firm’s price target on Zymeworks to $21 from $19 and keeps a Buy rating on the shares. Management’s decision to deprioritize the initiation of the previously-planned Phase 2 trial evaluating zanidatamab zovodotin and anti-PD-(L)1 mAb in HER2+ NSCLC “has little impact on our estimates” and valuation, says the analyst, who believes accelerating the development of the company’s earlier-stage pipeline of novel ADCs and TCEs will likely yield a “much higher” longer-term return on investment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZYME:
- Zymeworks Poised for Growth with Strong Cash Position
- Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
- Zymeworks Highlights Cancer Therapeutics at AACR
- Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
- ZYME Upcoming Earnings Report: What to Expect?